GO:0106222 lncRNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106222 (lncRNA binding) is a biological_process term that describes the binding of a long non-coding RNA (lncRNA) to a molecular target, most commonly an RNA-binding protein (RBP) or DNA, thereby modulating gene expression, mRNA stability, and chromatin architecture.
• lncRNA binding to RBPs is a central mechanism by which lncRNAs regulate mRNA stability in cancer progression and drug resistance.
• The interaction between lncRNAs and proteins can be studied using computational prediction tools such as LongTarget, which predicts lncRNA:DNA binding, and its revised version.
• Key lncRNAs involved in binding-mediated regulation include MALAT1, HOXB-AS3, KCNQ1OT1, and SNHG1, each linked to distinct biological processes and diseases.
• lncRNA binding is implicated in diverse pathologies, including colorectal cancer, osteoporosis and bone metastasis, and adipogenesis.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of lncRNA binding events in disease-relevant cell models.
Description
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that do not encode proteins but exert regulatory functions through interactions with other molecules. The Gene Ontology term GO:0106222, lncRNA binding, describes the biological process in which an lncRNA binds to a target molecule, such as an RNA-binding protein (RBP) or DNA, to modulate downstream cellular events. This binding activity is fundamental to lncRNA function, as it underlies mechanisms of mRNA stability control, chromatin folding, and transcriptional regulation. Understanding lncRNA binding is therefore critical for deciphering how these transcripts contribute to both normal physiology and disease. Recent reviews emphasize that lncRNA binding to RBPs regulates mRNA stability in cancer progression and drug resistance, highlighting its clinical relevance. Moreover, lncRNA-protein interactions are now recognized as a key to deciphering lncRNA mechanisms across biological contexts. As research advances, computational tools such as LongTarget have been developed to predict lncRNA:DNA binding, facilitating experimental design and functional validation. This article provides a research-grade overview of GO:0106222, covering its definition, core mechanisms, key genes, disease associations, and the CRISPR-based methods used to study it.
lncRNA binding At A Glance
| GO ID | GO:0106222 |
|---|---|
| GO term | lncRNA binding |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Binding of lncRNA to proteins or DNA to regulate gene expression, mRNA stability, and chromatin architecture |
| Related molecular entities | lncRNAs (e.g., MALAT1, HOXB-AS3, KCNQ1OT1, SNHG1) and RNA-binding proteins (e.g., HNRNPD) |
| Associated diseases | Colorectal cancer, osteoporosis and bone metastasis, adipogenesis-related disorders |
| Research methods | LongTarget prediction, RNA immunoprecipitation, CRISPR-based models |
What Is GO:0106222?
GO:0106222 (lncRNA binding) is a biological_process term that refers to the binding of a long non-coding RNA (lncRNA) to a molecular target, which can be a protein (e.g., an RNA-binding protein) or DNA. This binding event is a regulatory interaction that enables the lncRNA to influence processes such as mRNA stability, chromatin conformation, and gene expression. The term encompasses the physical association between the lncRNA and its binding partner, as well as the functional consequences of that interaction in cellular contexts.
Why Is lncRNA binding Important in Cell Biology?
lncRNA binding is a fundamental regulatory process that bridges non-coding RNA function and gene expression control. It is essential for understanding how lncRNAs modulate mRNA stability, chromatin folding, and transcriptional programs in both health and disease. Dysregulation of lncRNA binding has been linked to cancer progression, drug resistance, bone metastasis, and metabolic disorders, making it a promising target for therapeutic intervention and biomarker development.
• lncRNA binding to RBPs regulates mRNA stability, a process frequently hijacked in cancer progression and drug resistance.
• The lncRNA HOXB-AS3 encodes a peptide that suppresses colon cancer growth, illustrating how binding and coding potential can intersect.
• MALAT1 binding protects against osteoporosis and bone metastasis, highlighting its role in skeletal biology.
• KCNQ1OT1 regulates CDKN1C expression through promoter binding and chromatin folding, demonstrating lncRNA:DNA binding in imprinting control.
• SNHG1 recruits HNRNPD to stabilize SERPINA3 mRNA, promoting colorectal cancer metastasis.
• lncRNA-mediated adipogenesis involves binding interactions that control differentiation of adipocytes.
• Computational prediction of lncRNA:DNA binding using LongTarget aids in hypothesis generation for functional studies.
• lncRNA-protein interactions are central to deciphering lncRNA mechanisms across diverse biological processes.
What Happens During lncRNA binding?
Recognition and Target Selection
In simple terms: The lncRNA finds and attaches to its specific partner molecule, like a key fitting a lock.
During lncRNA binding, the lncRNA transcript recognizes and selectively associates with a target molecule, which may be an RNA-binding protein (RBP) or a DNA sequence. This recognition is mediated by sequence motifs and structural elements within the lncRNA. For example, the lncRNA SNHG1 recruits the HNRNPD protein to stabilize SERPINA3 mRNA, indicating a specific interaction that directs downstream effects. Similarly, KCNQ1OT1 binds to promoter regions and participates in chromatin folding to regulate CDKN1C expression. Computational tools such as LongTarget can predict lncRNA:DNA binding sites, aiding in the identification of target regions.
Formation of the lncRNA-Target Complex
In simple terms: Once attached, the lncRNA and its partner form a stable complex that can carry out a function.
After recognition, the lncRNA and its target form a stable complex. In the case of RBP binding, the lncRNA may act as a scaffold or guide to bring proteins together or to localize them to specific RNA transcripts. This complex formation is essential for the regulatory outcomes, such as mRNA stabilization. For instance, lncRNA binding to RBPs can regulate mRNA stability in cancer progression and drug resistance mechanisms. The interaction between lncRNAs and proteins is a key step in deciphering lncRNA mechanisms.
Functional Consequences: mRNA Stability and Chromatin Regulation
In simple terms: The complex then changes how genes are expressed, either by protecting mRNA or altering chromatin structure.
The formation of the lncRNA-target complex leads to functional outcomes that can affect gene expression at multiple levels. One major consequence is the regulation of mRNA stability: lncRNAs bound to RBPs can either stabilize or destabilize target mRNAs. For example, SNHG1 binding to HNRNPD stabilizes SERPINA3 mRNA, promoting colorectal cancer metastasis. Another outcome is chromatin regulation: KCNQ1OT1 binding to promoter regions and chromatin folding regulates CDKN1C expression in pigs. These functional consequences highlight the diverse roles of lncRNA binding in cellular physiology.
Regulation of lncRNA Binding
In simple terms: The binding process itself can be turned on or off by other cellular signals.
lncRNA binding is subject to regulation by various cellular factors, including the availability of binding partners, post-translational modifications of RBPs, and cellular stress conditions. The review by Zhang et al. (2024) discusses how lncRNA binding to RBPs regulates mRNA stability in cancer progression and drug resistance, implying that dysregulation of this process contributes to disease. Additionally, the interaction between lncRNAs and proteins can be modulated by developmental or metabolic cues, as seen in lncRNA-mediated adipogenesis.
Disease Implications of Dysregulated lncRNA Binding
In simple terms: When binding goes wrong, it can lead to diseases like cancer or bone disorders.
Dysregulation of lncRNA binding is associated with various human diseases. In cancer, aberrant lncRNA binding to RBPs can lead to increased mRNA stability of oncogenes or drug resistance factors. The lncRNA HOXB-AS3 encodes a peptide that suppresses colon cancer growth, indicating that binding-related functions can be tumor-suppressive. MALAT1 binding protects against osteoporosis and bone metastasis, suggesting a role in skeletal homeostasis. These examples underscore the clinical relevance of understanding lncRNA binding mechanisms.
Key Genes Involved in GO:0106222 lncRNA binding
The following genes and lncRNAs are key players in lncRNA binding processes, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MALAT1 | lncRNA that protects against osteoporosis and bone metastasis | Studied in bone biology and metastasis models |
| HOXB-AS3 | lncRNA encoding a peptide that suppresses colon cancer growth | Implicated in colorectal cancer |
| KCNQ1OT1 | Imprinted lncRNA regulating CDKN1C via promoter binding and chromatin folding | Model for imprinting and chromatin regulation |
| SNHG1 | lncRNA recruiting HNRNPD to stabilize SERPINA3 mRNA | Promotes colorectal cancer metastasis |
| HNRNPD | RNA-binding protein recruited by SNHG1 | Involved in mRNA stability |
| SERPINA3 | mRNA stabilized by SNHG1-HNRNPD complex | Associated with cancer metastasis |
| CDKN1C | Target gene regulated by KCNQ1OT1 binding | Implicated in growth and development |
| Various RBPs | Bind lncRNAs to regulate mRNA stability | Central to cancer progression and drug resistance |
| lncRNAs in adipogenesis | Regulate adipocyte differentiation | Metabolic research |
| LongTarget-predicted lncRNA:DNA interactions | Computational prediction of binding | Aids experimental design |
| lncRNA-protein complexes | Functional units in gene regulation | General lncRNA mechanisms |
How Is lncRNA binding Regulated?
lncRNA binding is regulated at multiple levels, including the expression levels of the lncRNA and its binding partners, post-translational modifications of RNA-binding proteins, and cellular signaling pathways. The review by Zhang et al. (2024) highlights that lncRNA binding to RBPs regulates mRNA stability in cancer progression and drug resistance, suggesting that dysregulation of this process is linked to disease. Additionally, lncRNA-mediated adipogenesis is controlled by developmental and metabolic cues. However, specific regulatory pathways such as mTOR or ISR are not directly cited in the provided literature for this term.
lncRNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SNHG1 | Colorectal cancer metastasis | Knockout or knockdown in colorectal cancer cell lines |
| HOXB-AS3 | Colon cancer growth suppression | Overexpression or knockout in colon cancer cells |
| MALAT1 | Osteoporosis and bone metastasis | Knockout in osteoblast or cancer cell lines |
| KCNQ1OT1 | Imprinting and developmental regulation | Knockout in porcine or mammalian cell models |
| lncRNAs in adipogenesis | Adipocyte differentiation and metabolic disorders | Overexpression or knockout in preadipocyte cell lines |
Cancer Progression and Drug Resistance
lncRNA binding to RNA-binding proteins plays a critical role in regulating mRNA stability, which can contribute to cancer progression and drug resistance. The review by Zhang et al. (2024) discusses how these interactions modulate gene expression programs that promote tumor growth and survival. Specific examples include SNHG1, which recruits HNRNPD to stabilize SERPINA3 mRNA, thereby facilitating colorectal cancer metastasis. Additionally, the lncRNA HOXB-AS3 encodes a peptide that suppresses colon cancer growth, indicating that lncRNA binding and coding potential can intersect in tumor suppression.
Bone Metastasis and Osteoporosis
The lncRNA MALAT1 has been shown to protect against osteoporosis and bone metastasis, highlighting the importance of lncRNA binding in skeletal biology. Although the exact binding partners and mechanisms are not fully detailed in the provided citation, this finding suggests that MALAT1 interactions contribute to bone homeostasis and disease prevention.
Imprinting and Developmental Disorders
The imprinted lncRNA KCNQ1OT1 regulates CDKN1C expression through promoter binding and chromatin folding, a process critical for normal development. Dysregulation of this binding event could lead to imprinting disorders, although direct disease associations are not specified in the cited study.
Metabolic Disorders and Adipogenesis
lncRNA-mediated adipogenesis involves binding interactions that control the differentiation of adipocytes. While specific diseases are not directly linked in the cited review, aberrant adipogenesis is associated with obesity and metabolic syndrome, suggesting a potential role for lncRNA binding in these conditions.
From lncRNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a specific lncRNA affect mRNA stability? | CRISPR knockout of the lncRNA gene in cancer cell lines |
| Does a point mutation in the lncRNA binding motif alter protein interaction? | CRISPR point mutation knock-in of the binding site |
| Can knock-in of a tagged lncRNA reveal binding partners? | Tagged knock-in (e.g., MS2 or biotin tags) followed by pulldown |
| Does overexpression of a lncRNA promote metastasis? | Overexpression of the lncRNA in cancer cell lines |
| Does knockout of an RBP affect lncRNA-mediated mRNA stabilization? | CRISPR knockout of the RBP in relevant cell models |
| Can chromatin folding be disrupted by deleting a lncRNA promoter-binding region? | CRISPR deletion of the binding region in cell lines |
How to Study the lncRNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LongTarget | Predicted lncRNA:DNA binding sites | Computational screening of lncRNA targets |
| RNA immunoprecipitation (RIP) | Physical interaction between lncRNA and protein | Identifying binding partners |
| CLIP-seq | Transcriptome-wide binding sites of RBPs | Mapping lncRNA-protein interactions |
| mRNA stability assay | Half-life of target mRNAs | Assessing functional impact of lncRNA binding |
| CRISPR knockout | Loss-of-function of lncRNA or RBP | Determining causality in disease models |
| CRISPR point mutation | Effect of specific binding site mutation | Dissecting binding motifs |
| CRISPR knock-in | Tagged or reporter lncRNA | Visualizing and pulldown of lncRNA complexes |
| Overexpression | Gain-of-function of lncRNA | Testing oncogenic or protective roles |
Computational Prediction of lncRNA Binding
Computational tools such as LongTarget and its revised version are used to predict lncRNA:DNA binding interactions. These tools analyze sequence complementarity and structural features to identify potential binding sites, providing a starting point for experimental validation.
RNA Immunoprecipitation (RIP) and Cross-Linking
RNA immunoprecipitation (RIP) and cross-linking immunoprecipitation (CLIP) are used to detect physical interactions between lncRNAs and RNA-binding proteins. These methods involve immunoprecipitating the protein of interest and sequencing the associated RNAs to identify binding sites.
Functional Assays for mRNA Stability
To assess the functional consequences of lncRNA binding on mRNA stability, researchers use actinomycin D or other transcription inhibitors followed by quantitative PCR to measure mRNA half-lives. This approach has been used to study how lncRNAs like SNHG1 stabilize target mRNAs.
CRISPR-Based Genetic Models
CRISPR-Cas9 technology enables the generation of knockout, point mutation, knock-in, and overexpression models to study lncRNA binding. These models allow causal interrogation of specific binding events and their downstream effects in disease-relevant cell types.
How CRISPR Can Be Used to Study GO:0106222 lncRNA binding
Knockout
CRISPR knockout of lncRNA genes or their binding partners is used to determine loss-of-function phenotypes. For example, knocking out SNHG1 or HNRNPD can reveal their roles in stabilizing SERPINA3 mRNA and promoting cancer metastasis. Knockout models are essential for establishing causality in lncRNA binding research.
Point Mutation
CRISPR point mutation can be used to introduce specific mutations in lncRNA binding motifs or in the interacting domains of RNA-binding proteins. This allows researchers to dissect the precise sequence requirements for binding and to test whether a single nucleotide change affects downstream functions.
Knock-in
Knock-in of tagged lncRNAs (e.g., with MS2, biotin, or fluorescent tags) enables visualization and biochemical isolation of lncRNA-protein complexes. This approach is valuable for identifying novel binding partners and for tracking lncRNA localization in live cells.
Overexpression
Overexpression of a lncRNA can be achieved by CRISPR activation (CRISPRa) or by lentiviral delivery. This is used to test gain-of-function effects, such as whether overexpression of MALAT1 protects against osteoporosis or whether overexpression of an oncogenic lncRNA promotes metastasis.
How EDITGENE Supports lncRNA binding Research
Researchers studying lncRNA binding-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations.
Contact EDITGENE today to design your custom CRISPR model for lncRNA binding research.
Frequently Asked Questions About lncRNA binding
What is GO:0106222 lncRNA binding?
GO:0106222 is a Gene Ontology biological_process term that describes the binding of a long non-coding RNA (lncRNA) to a target molecule, such as an RNA-binding protein or DNA, to regulate gene expression and mRNA stability.
What genes are involved in lncRNA binding?
Key genes include MALAT1, HOXB-AS3, KCNQ1OT1, and SNHG1, as well as RNA-binding proteins like HNRNPD.
How does lncRNA binding regulate mRNA stability?
lncRNAs can bind to RNA-binding proteins and form complexes that protect or destabilize target mRNAs, thereby controlling their half-lives and expression levels.
What diseases are associated with lncRNA binding?
Dysregulated lncRNA binding is linked to cancer progression, drug resistance, osteoporosis, bone metastasis, and metabolic disorders.
What methods are used to study lncRNA binding?
Methods include computational prediction (LongTarget), RNA immunoprecipitation, CLIP-seq, mRNA stability assays, and CRISPR-based genetic models.
Can CRISPR be used to study lncRNA binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal interrogation of lncRNA binding events in disease-relevant cells.
What is the role of MALAT1 in lncRNA binding?
MALAT1 is an lncRNA that protects against osteoporosis and bone metastasis, likely through binding interactions with proteins or DNA.
How does SNHG1 promote cancer metastasis?
SNHG1 binds to HNRNPD and recruits it to stabilize SERPINA3 mRNA, which promotes colorectal cancer metastasis.
What is LongTarget?
LongTarget is a computational tool for predicting lncRNA:DNA binding interactions, and its revised version improves prediction accuracy.
Why is lncRNA binding important for drug resistance?
lncRNA binding to RBPs can stabilize mRNAs encoding drug resistance factors, contributing to cancer therapy failure.
Conclusion
GO:0106222 (lncRNA binding) is a critical biological process that underlies the regulatory functions of long non-coding RNAs. Through binding to RNA-binding proteins or DNA, lncRNAs modulate mRNA stability, chromatin architecture, and gene expression, with profound implications for cancer, bone disease, and metabolic disorders. Advances in computational prediction and CRISPR-based models are accelerating the dissection of these interactions, offering new opportunities for therapeutic targeting. Continued research into lncRNA binding mechanisms will be essential for translating these insights into clinical applications.
References
- 1. Zhang N et al.. 2024. The role of lncRNA binding to RNA‑binding proteins to regulate mRNA stability in cancer progression and drug resistance mechanisms (Review).. Oncol Rep 52(5) PMID: 39219266
- 2. Huang JZ et al.. 2017. A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth.. Mol Cell 68(1):171-184.e6 PMID: 28985503
- 3. Zhao Y et al.. 2024. Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis.. Nat Commun 15(1):2384 PMID: 38493144
- 4. Zhou Y et al.. 2024. Imprinted lncRNA KCNQ1OT1 regulates CDKN1C expression through promoter binding and chromatin folding in pigs.. Gene 923:148590 PMID: 38772516
- 5. Zhang P et al.. 2022. LncRNA-Mediated Adipogenesis in Different Adipocytes.. Int J Mol Sci 23(13) PMID: 35806493
- 6. Lin J et al.. 2026. LncRNA:DNA Binding Prediction Using LongTarget and Its Revised Version.. Methods Mol Biol 2949:141-161 PMID: 41174201
- 7. Yang H et al.. 2024. LncRNA SNHG1 facilitates colorectal cancer cells metastasis by recruiting HNRNPD protein to stabilize SERPINA3 mRNA.. Cancer Lett 604:217217 PMID: 39233042
- 8. Wang Z et al.. 2025. LncRNA-Protein Interactions: A Key to Deciphering LncRNA Mechanisms.. Biomolecules 15(6) PMID: 40563521
